Serum metabolite biomarkers discriminate healthy smokers from COPD smokers

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Chen, Qiuying ^a   Deeb, Ruba S ^a   Ma, Yuliang ^a   Staudt, Michelle R ^a   Crystal, Ronald G ^a   Gross, Steven S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,7 DIMETHYLURIC ACID; 1ALPHA,25 DIHYDROXY 23 THIAVITAMIN D3; 2 METHYLHIPPURIC ACID; 3 HYDROXYCOTININE; 3 HYDROXYVALERATE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; 5 ACETYLAMINO 6 AMINO 3 METHYLURACIL; 6 METHYLTETRAHYDROPTERIN; BIOLOGICAL MARKER; CARBOXYLHEMOGLOBIN; COTININE; CREATININE; CYSTEINE SULFINIC ACID; FIBRINOGEN PEPTIDE B; FUMARIC ACID; GLYCEROPHOSPHOINOSITOL; GLYCOCHENODEOXYCHOLATE 3 SULFATE; GLYCOCHENODEOXYCHOLIC ACID 3 GLUCURONIDE; INOSITOL; NICOTINIC ACID METHYL ESTER; QUINIC ACID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LIQUID CHROMATOGRAPHY; LUNG DIFFUSION CAPACITY; MALE; MASS SPECTROMETRY; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; TOTAL LUNG CAPACITY; BLOOD; CASE CONTROL STUDY; CLUSTER ANALYSIS; LUNG FUNCTION TEST; METABOLOME; METABOLOMICS; MIDDLE AGED; NORMAL HUMAN; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CLUSTER ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTHY VOLUNTEERS; HUMANS; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS; SMOKING;

EID: 84956874199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143937     Document Type: Article

References (80)

1. Koutsokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respiratory research. 2013; 14:111. doi: 10.1186/1465-9921-14-111 PMID: 24143945; PubMed Central PMCID: PMC4014989.
2. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011; 155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008 PMID: 21810710.
3. Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respiratory medicine. 2014; 108(5):729-36. Epub 2014/03/29. doi: 10. 1016/j.rmed.2014.03.002 PMID: 24675239.
4. Lopez-Campos JL, Calero C, Lopez-Ramirez C, Asensio-Cruz MI, Marquez-Martin E, Ortega-Ruiz F. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient preference and adherence. 2015; 9:95-104. Epub 2015/02/06. doi: 10.2147/PPA.S55009 PMID: 25653503; PubMed Central PMCID: PMC4303404.
5. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respiratory research. 2011; 12:40. Epub 2011/04/12. doi: 10.1186/1465-9921-12-40 PMID: 21477298; PubMed Central PMCID: PMC3090353.
6. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Translational research: the journal of laboratory and clinical medicine. 2012; 159(4):228-37. doi: 10.1016/j.trsl.2012. 01.019 PMID: 22424427.
7. Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? International journal of chronic obstructive pulmonary disease. 2014; 9:163-77. doi: 10.2147/COPD.S42362 PMID: 24532968; PubMed Central PMCID: PMC3923613.
8. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013; 68(7):670-6. doi: 10.1136/thoraxjnl-2012-201871 PMID: 22744884; PubMed Central PMCID: PMC3711372.
9. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2001; 164(6):1008-11. doi: 10.1164/ajrccm. 164.6.2010067 PMID: 11587987.
10. Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clinical chemistry and laboratory medicine: CCLM/FESCC. 2015; 53(4):521-39. doi: 10.1515/cclm-2014-0748 PMID: 25252756.
11. Kurt OK, Tosun M, Kurt EB, Talay F. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation. 2015; 38(1):89-93. doi: 10.1007/s10753-014-0010-3 PMID: 25303877.
12. Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. The American journal of the medical sciences. 2015; 349(1):29-35. doi: 10.1097/MAJ.0000000000000332 PMID: 25233043.
13. Barouchos N, Papazafiropoulou A, Iacovidou N, Vrachnis N, Barouchos N, Armeniakou E, et al. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations. Scandinavian journal of clinical and laboratory investigation. 2015; 75(2):126-32. doi: 10.3109/00365513.2014.992944 PMID: 25598350.
14. Shaw JG, Vaughan A, Dent AG, O'Hare PE, Goh F, Bowman RV, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). Journal of thoracic disease. 2014; 6(11):1532-47. doi: 10.3978/j.issn.2072-1439.2014.11.33 PMID: 25478195; PubMed Central PMCID: PMC4255159.
15. Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clinical chemistry and laboratory medicine: CCLM/FESCC. 2014. doi: 10.1515/cclm-2014-0748 PMID: 25252756.
16. Johansson SL, Roberts NB, Schlosser A, Andersen CB, Carlsen J, Wulf-Johansson H, et al. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respiratory medicine. 2014; 108(9):1336-44. doi: 10.1016/j.rmed.2014.06.003 PMID: 25022422.
17. Heo JS, Park JS, Lee EJ, Kim TH, Jang AS, Park SW, et al. Retinoic acid receptor alpha: One of plasma biomarkers associated with exacerbation of chronic obstructive pulmonary disease. Copd. 2014; 11 (2):152-62. doi: 10.3109/15412555.2013.828028 PMID: 24111541.
18. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013; 309(22):2353-61. doi: 10. 1001/jama.2013.5732 PMID: 23757083.
19. Pastor MD, Nogal A, Molina-Pinelo S, Melendez R, Romero-Romero B, Mediano MD, et al. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. International journal of molecular sciences. 2013; 14(2):3440-55. doi: 10.3390/ijms14023440 PMID: 23389041; PubMed Central PMCID: PMC3588051.
20. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Annals of medicine. 2013; 45(3):291-300. doi: 10.3109/07853890.2012.732703 PMID: 23110517.
21. El-Deek SE, Makhlouf HA, Saleem TH, Mandour MA, Mohamed NA. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Medical principles and practice: international journal of the Kuwait University, Health Science Centre. 2013; 22(5):469-74. doi: 10.1159/000349934 PMID: 23860258.
22. Dickens JA, Lomas DA. CC-16 as a biomarker in chronic obstructive pulmonary disease. Copd. 2012; 9(5):574-5. doi: 10.3109/15412555.2012.718926 PMID: 23030587.
23. Bowler RP. Surfactant protein D as a biomarker for chronic obstructive pulmonary disease. Copd. 2012; 9(6):651-3. doi: 10.3109/15412555.2012.736317 PMID: 23244171.
24. Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2011; 183(12):1633-43. doi: 10.1164/rccm.201010-1623OC PMID: 21471098.
25. Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2011; 184 (6):637-41. doi: 10.1164/rccm.201103-0450PP PMID: 21757624.
26. Rana GS, York TP, Edmiston JS, Zedler BK, Pounds JG, Adkins JN, et al. Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Analytical and bioanalytical chemistry. 2010; 397(5):1809-19. doi: 10.1007/s00216-010-3742-4 PMID: 20442989.
27. Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine. 2010; 50(2):152-7. doi: 10.1016/j.cyto.2010.02.004 PMID: 20181491.
28. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respiratory medicine. 2009; 103 (8):1231-8. doi: 10.1016/j.rmed.2009.01.021 PMID: 19249197.
29. Pinto-Plata V, Toso J, Lee K, Bilello J, Mullerova H, De Souza M, et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proceedings of the American Thoracic Society. 2006; 3(6):465-6. doi: 10.1513/pats. 200603-030MS PMID: 16921105.
30. Suzuki M, Makita H, Ostling J, Thomsen LH, Konno S, Nagai K, et al. Lower leptin/adiponectin ratio and risk of rapid lung function decline in chronic obstructive pulmonary disease. Annals of the American Thoracic Society. 2014; 11(10):1511-9. doi: 10.1513/AnnalsATS.201408-351OC PMID: 25372271.
31. Carolan BJ, Kim YI, Williams AA, Kechris K, Lutz S, Reisdorph N, et al. The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2013; 188(5):561-6. doi: 10.1164/rccm.201212-2299OC PMID: 23777323; PubMed Central PMCID: PMC3827701.
32. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scandinavian journal of clinical and laboratory investigation. 2009; 69(2):219-24. doi: 10.1080/00365510802474400 PMID: 18946779.
33. Dahl M. Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein. American journal of respiratory and critical care medicine. 2008; 177(11):1177-8. doi: 10.1164/rccm.200802-225ED PMID: 18487618.
34. Wu H, Yang S, Wu X, Zhao J, Zhao J, Ning Q, et al. Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. Biochemical and biophysical research communications. 2014; 450 (1):110-6. doi: 10.1016/j.bbrc.2014.05.073 PMID: 24866242.
35. He H, Tao Y, Chen X, Qiu H, Zhu J, Zhang J, et al. High levels of interleukin-6 and 8-iso-prostaglandin in the exhaled breath condensate and serum of patients with chronic obstructive pulmonary disease related pulmonary hypertension. Chinese medical journal. 2014; 127(9):1608-12. PMID: 24791862.
36. Liang R, Zhang W, Song YM. Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. Molecular medicine reports. 2013; 7(5):1470-6. doi: 10.3892/mmr.2013.1377 PMID: 23525184.
37. Petersen AM, Penkowa M, Iversen M, Frydelund-Larsen L, Andersen JL, Mortensen J, et al. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung. 2007; 185(3):161-71. doi: 10.1007/s00408-007-9000-7 PMID: 17436040.
38. Fuster A, Sauleda J, Sala E, Barcelo B, Pons J, Carrera M, et al. Systemic inflammation after inspiratory loading in chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2008; 3(1):149-53. PMID: 18488438; PubMed Central PMCID: PMC2528210.
39. Chan KH, Yeung SC, Yao TJ, Ip MS, Cheung AH, Chan-Yeung MM, et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2010; 14(9):1193-200. PMID: 20819268.
40. Wang M, Huang Y, Liang Z, Liu D, Lu Y, Dai Y, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. The clinical respiratory journal. 2014. doi: 10.1111/crj.12194 PMID: 25102970.
41. Akbas F, Coskunpinar E, Aynaci E, Oltulu YM, Yildiz P. Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Experimental lung research. 2012; 38(6):286-94. doi: 10.3109/01902148.2012.689088 PMID: 22686440.
42. Csanky E, Ruhl R, Scholtz B, Vasko A, Takacs L, Hempel WM. Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls. Electrophoresis. 2009; 30(7):1228-34. doi: 10.1002/elps.200800722 PMID: 19294692.
43. Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. American journal of respiratory and critical care medicine. 2015; 191(3):275-84. doi: 10.1164/rccm.201410-1771OC PMID: 25494452.
44. Deja S, Porebska I, Kowal A, Zabek A, Barg W, Pawelczyk K, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. Journal of pharmaceutical and biomedical analysis. 2014; 100:369-80. doi: 10.1016/j.jpba.2014.08.020 PMID: 25213261.
45. Scott JA, Duongh M, Young AW, Subbarao P, Gauvreau GM, Grasemann H. Asymmetric dimethylarginine in chronic obstructive pulmonary disease (ADMA in COPD). International journal of molecular sciences. 2014; 15(4):6062-71. doi: 10.3390/ijms15046062 PMID: 24727374; PubMed Central PMCID: PMC4013615.
46. Markoulis N, Gourgoulianis KI, Moulas A, Gerogianni E, Molyvdas AP. Reactive oxygen metabolites as an index of chronic obstructive pulmonary disease severity. Panminerva medica. 2006; 48(4):209-13. PMID: 17215792.
47. Musharraf SG, Mazhar S, Choudhary MI, Rizi N, Atta Ur R. Plasma Metabolite Profiling and Chemometric Analyses of Lung Cancer along with Three Controls through Gas Chromatography-Mass Spectrometry. Scientific reports. 2015; 5:8607. doi: 10.1038/srep08607 PMID: 25712604; PubMed Central PMCID: PMC4339805.
48. Paige M, Burdick MD, Kim S, Xu J, Lee JK, Shim YM. Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype. Biochemical and biophysical research communications. 2011; 413(4):588-93. doi: 10.1016/j.bbrc.2011.09.006 PMID: 21925153; PubMed Central PMCID: PMC3199021.
49. Ten Hoeve AL, Roda MA, Redegeld F, Folkerts G, Blalock JE, Gaggar A. Proline-glycine-proline as a potential biomarker in chronic obstructive pulmonary disease and cystic fibrosis. Tanaffos. 2012; 11 (2):12-5. PMID: 25191408; PubMed Central PMCID: PMC4153190.
50. Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Gorski P. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Archives of medical science: AMS. 2012; 8(2):277-85. doi: 10.5114/aoms.2012.28555 PMID: 22662001; PubMed Central PMCID: PMC3361040.
51. Diaz AA, Valim C, Yamashiro T, Estepar RS, Ross JC, Matsuoka S, et al. Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers. Chest. 2010; 138(4):880-7. doi: 10.1378/chest.10-0542 PMID: 20558554; PubMed Central PMCID: PMC2951760.
52. Bentley AR, Emrani P, Cassano PA. Genetic variation and gene expression in antioxidant related enzymes and risk of COPD: a systematic review. Thorax. 2008; 63(11):956-61. doi: 10.1136/thx.2007. 086199 PMID: 18566111; PubMed Central PMCID: PMC3032799.
53. Ning W, Lee J, Kaminski N, Feghali-Bostwick CA, Watkins SC, Pilewski JM, et al. Comprehensive analysis of gene expression on GOLD-2 Versus GOLD-0 smokers reveals novel genes important in the pathogenesis of COPD. Proceedings of the American Thoracic Society. 2006; 3(6):466. doi: 10.1513/pats.200603-031MS PMID: 16921106.
54. Zhang J, Wang X, Chen Y, Yao W. Exhaled Hydrogen Sulfide Predicts Airway Inflammation Phenotype in COPD. Respiratory care. 2015; 60(2):251-8. doi: 10.4187/respcare.03519 PMID: 25336529.
55. Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. BioMed research international. 2014; 2014:271918. doi: 10.1155/2014/271918 PMID: 24719850; PubMed Central PMCID: PMC3955647.
56. Papaioannou AI, Loukides S, Minas M, Kontogianni K, Bakakos P, Gourgoulianis KI, et al. Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers. Respiratory research. 2011; 12:67. doi: 10.1186/1465-9921-12-67 PMID: 21600044; PubMed Central PMCID: PMC3120669.
57. Nobakht MGBF, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2015; 20(1):5-16. doi: 10.3109/1354750X.2014.983167 PMID: 25403491.
58. Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Molecular bioSystems. 2012; 8(12):3125-33. doi: 10.1039/c2mb25194a PMID: 23051772.
59. Chen Q, Park HC, Goligorsky MS, Chander P, Fischer SM, Gross SS. Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice. PloS one. 2012; 7(6):e37149. Epub 2012/06/23. doi: 10.1371/journal.pone.0037149 PMID: 22723833; PubMed Central PMCID: PMC3377762.
60. Ismailoglu I, Chen Q, Popowski M, Yang L, Gross SS, Brivanlou AH. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Developmental biology. 2014; 391(2):230-40. Epub 2014/05/02. doi: 10.1016/j.ydbio.2014.04.005 PMID: 24780625; PubMed Central PMCID: PMC4109978.
61. Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. The Journal of clinical investigation. 1986; 77(3):1014-9. doi: 10.1172/JCI112353 PMID: 3005361; PubMed Central PMCID: PMC423507.
62. Mannino DM, Tal-Singer R, Lomas DA, Vestbo J, Graham Barr R, Tetzlaff K, et al. Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic obstructive pulmonary diseases. 2015; 2(1):23-34. doi: 10.15326/jcopdf.2.1.2014.0138 PMID: 25685850; PubMed Central PMCID: PMC4326107.
63. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thrombosis and haemostasis. 2000; 84(2):210-5. PMID: 10959691.
64. Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen - fibrin transition in blood coagulation. Nature. 1978; 275(5680):501-5. PMID: 692730.
65. Eckhardt T, Nossel HL, Hurlet-Jensen A, La Gamma KS, Owen J, Auerbach M. Measurement of desarginine fibrinopeptide B in human blood. The Journal of clinical investigation. 1981; 67(3):809-16. doi: 10.1172/JCI110098 PMID: 7204556; PubMed Central PMCID: PMC370632.
66. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thrombosis and haemostasis. 2009; 102(6):1176-82. doi: 10.1160/TH09-02-0118 PMID: 19967149.
67. Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2005; 2(1):71-7. doi: 10.1513/pats.200407-038MS PMID: 16113472.
68. Polosa R, Malerba M, Cacciola RR, Morjaria JB, Maugeri C, Prosperini G, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Internal and emergency medicine. 2013; 8(7):567-74. doi: 10.1007/s11739-011-0636-1 PMID: 21660493.
69. Dessi A, Fanos V. Myoinositol: a new marker of intrauterine growth restriction? Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 2013; 33(8):776-80. doi: 10.3109/01443615.2013.831046 PMID: 24219712.
70. Han W, Gills JJ, Memmott RM, Lam S, Dennis PA. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer prevention research. 2009; 2(4):370-6. doi: 10.1158/1940-6207.CAPR-08-0209 PMID: 19336734; PubMed Central PMCID: PMC3715041.
71. Sriskantharajah S, Hamblin N, Worsley S, Calver AR, Hessel EM, Amour A. Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases. Annals of the New York Academy of Sciences. 2013; 1280:35-9. doi: 10.1111/nyas.12039 PMID: 23551101.
72. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Therapeutic advances in respiratory disease. 2010; 4(1):19-34. doi: 10.1177/1753465809352792 PMID: 20051446.
73. Dinavahi SS, Nyayapathy S, Perumal Y, Dharmarajan S, Viswanadha S. Combined inhibition of PDE4 and PI3Kdelta modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease. Drug research. 2014; 64(4):214-9. doi: 10.1055/s-0033-1355411 PMID: 24105104.
74. Girod S, Galabert C, Lecuire A, Zahm JM, Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatric pulmonology. 1992; 13(1):22-7. PMID: 1589308.
75. Rothwell JA, Fillatre Y, Martin JF, Lyan B, Pujos-Guillot E, Fezeu L, et al. New biomarkers of coffee consumption identified by the non-targeted metabolomic profiling of cohort study subjects. PloS one. 2014; 9(4):e93474. doi: 10.1371/journal.pone.0093474 PMID: 24713823; PubMed Central PMCID: PMC3979684.
76. Allred KF, Yackley KM, Vanamala J, Allred CD. Trigonelline is a novel phytoestrogen in coffee beans. The Journal of nutrition. 2009; 139(10):1833-8. doi: 10.3945/jn.109.108001 PMID: 19710155.
77. Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sorgel F, Fuhr U. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? European journal of clinical pharmacology. 2009; 65(4):411-7. doi: 10.1007/s00228-008-0597-0 PMID: 19082994.
78. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clinical pharmacology and therapeutics. 1991; 49(6):648-57. PMID: 2060254.
79. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomedical chromatography: BMC. 2007; 21(2):190-200. doi: 10.1002/bmc.736 PMID: 17221922.
80. Grygiel JJ, Birkett DJ. Cigarette smoking and theophylline clearance and metabolism. Clinical pharmacology and therapeutics. 1981; 30(4):491-6. PMID: 7285483.